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Summary
Health professionals are expected to be 
familiar with common and clinically significant 
complementary medicine interactions or at 
least know where to look them up. Knowing 
the dynamic and kinetic interactions associated 
with commonly used complementary medicines 
helps to identify the risk of drug interactions. 
Although information on complementary 
medicine interactions is not readily provided by 
the manufacturers, evidence is available by way 
of case reports, independent research and web-
based resources, which have increased in recent 
years. Collectively, these data make interactions 
with complementary medicines largely 
predictable and therefore preventable. 
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Introduction
The Therapeutic Goods Administration refers to complementary 
medicines as 'medicinal products containing herbs, vitamins, 
minerals, nutritional supplements, homoeopathic medicines, 
traditional medicines and certain aromatherapy products'.1 In 
Australia, complementary medicines are largely regulated as 
unscheduled medicines, and are usually self-selected. 
Complementary medicines are very popular among Australians, 
with surveys indicating that up to 60% of people use at least 
one complementary medicine on a regular basis. However, 
about 50% of consumers also report using a conventional 
medicine on the same day as their complementary medicine.2,3 
It is not surprising, therefore, that healthcare professionals and 
consumers alike are concerned about the potential for drug 
interactions between these medicines. 
As so many Australians use complementary medicines, including 
children, the elderly, patients with chronic disease, mental health 
disorders and cancer, it is important that prescribers always 
ask what complementary products their patients are taking 
in addition to any conventional medicines. Knowing this, and 
extrapolating reported pharmacodynamic and pharmacokinetic 
outcomes, can help predict potential drug interactions. 
Polypharmacy
Complementary medicines are frequently used in the context of 
polypharmacy. A study of 3070 elderly people found that 74.2% 
took at least one prescription drug and one complementary 
medicine, with 32.5% of them using three or more prescription 
medicines with three or more complementary medicines.4 This 
translates to an increased risk of drug interactions. In a study of 
458 US Veterans' Administration patients, 197 of them reported 
taking complementary medicines combined with prescription 
medicines. Of these patients, 45% had potential for interactions, 
which was rated as serious in 6% of patients.5 In another study 
which interviewed 3000 people (aged 57−85) about prescription, 
over-the-counter and complementary medicine use, 4% of 
them were potentially at risk of a major drug–drug interaction.6 
It has been suggested that once a patient is on eight or more 
medicines, regardless of origin, there is a 100% chance of a 
drug interaction occurring.7
Drug interactions 
As with other drugs, complementary medicine interactions 
can be broadly classified by their mechanism, that is, 
pharmacodynamic and pharmacokinetic. The former are due to 
overlap of pharmacological actions, while the latter result from 
changes in absorption, distribution, metabolism or excretion. 
Risk factors for significant complementary medicine interactions 
are the same as for conventional medicines. These include 
patient characteristics (such as extremes of age, frailty, female 
gender, cognition, comorbities and genetic disposition) and 
medication factors (such as high medication burden, recent 
changes in medicines, drugs with a low therapeutic index and 
limited elimination pathways). 
Due to their complex chemical structure, herbal medicines are 
prone to interactions via the oxidative cytochrome P450 system 
or the efflux drug transporter P-glycoprotein.8,9 In vitro assays, 
using human tissue or cell lines, are frequently used to 
determine whether a herb affects these enzymes.10 However, in 
vitro findings do not necessarily correlate with what happens 
in the human body. As several herbal medicines and many 
prescription drugs are substrates, inducers or inhibitors of CYP 
isoenzymes or P-glycoprotein, interactions can ensue when they 
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are used concomitantly.9 A classic example is St John's wort, 
which has kinetic interactions with a wide range of drugs via the 
induction of CYP1A2, CYP3A4, CYP2C9 and P-glycoprotein.11 
This lowers the concentration of the concomitant drug. 
Table 1 shows selected documented interactions which have 
been chosen based on a composite of: 
n the most frequently used complementary medicines in 
Australia, from survey and sales data12
n interactions with serious or clinically significant outcomes.
Table 1 categorises interactions by their possible outcome, severity,  
supporting evidence and proposed mechanism. Generic guidance 
on interaction management is given in the key, within the definitions 
of severity (major, moderate, minor). Certain therapeutic drug 
classes appear repeatedly in the table such as antiplatelet drugs,  
anticoagulants, antidepressants, antihypertensives, hypoglycaemics, 
immunosuppressants, antiretrovirals and hormones. Health  
professionals should monitor patients closely when a complementary  
medicine is taken concomitantly with these drugs.
Table 1
Evidence-based complementary medicine interactions 8,11,13,14 
This table shows complementary medicines with at least one 'major' interaction. For the full version of this table, see this article online 
at www.australianprescriber.com 
Complementary 
medicine 
Interacting drug Possible outcome Severity and level  
of evidence*
Proposed mechanisms/
comment
Evening  
primrose oil
Antiplatelet drugs, warfarin ↑ drug effect Major, level B Contains gamma-linolenic 
acid, probable anticoagulant
Garlic Contraceptives, oral ↓ drug effect  Moderate, level D Induces CYP3A4
Saquinavir/non-nucleoside 
reverse transcriptase 
inhibitors
↓ drug levels and 
effect 
Major, level B Induces CYP3A4 
Antiplatelet drugs, warfarin ↑ bleeding risk Moderate, level D Theoretical antiplatelet activity 
Ginkgo Anticonvulsants ↑ seizure risk Moderate, level D Large amounts of ginkgotoxin 
can cause neurotoxicity
Warfarin, antiplatelet drugs ↑ bleeding risk Major, level D Antiplatelet activity after 
several weeks
CYP2C9 substrates e.g. 
glipizide, warfarin, celecoxib
↑ substrate levels Moderate, level D Inhibits CYP2C9 activity 
CYP1A2, CYP2C19, CYP2D6 
and CYP3A4 substrates 
↑ substrate levels Moderate, level B Potentially inhibits these 
enzymes 
Hypoglycaemic drugs ↑ ↓ drug effect Moderate, level B Variably affects blood glucose 
concentrations
Glucosamine Warfarin ↑ bleeding risk Major, level D Several case reports of 
increased INR
Hawthorn Calcium channel blockers, 
nitrates, phosphodiesterase 
inhibitors
↑ drug effect Major, level D Additive vasodilator effects
Digoxin, beta blockers ↑ drug effect Major, level D Additive effects on heart 
rate and/or blood pressure. 
Hawthorn has cardiotonic 
effects.
Kava CNS depressants ↑ drug effect Major, level A Additive somnolence
CYP1A2, CYP2D6, CYP2C9, 
CYP2E1, CYP3A4 substrates 
↑ substrate levels Moderate, level B
Kava potentially inhibits these 
enzymes
P-glycoprotein substrates ↑ substrate levels Moderate, level D
St John's wort Alprazolam ↓ drug levels and 
effect
Major, level B Increased clearance; half-life 
reduced by 50%
Amitriptyline ↑ drug effect Major, level B
Increased risk of serotonin 
syndrome 
Antidepressants, tramadol ↑ drug effect Major, level D
Pethidine ↑ drug effect Major, level D
Triptans ↑ drug effect Moderate, level D
}
}
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Complementary 
medicine 
Interacting drug Possible outcome Severity and level  
of evidence*
Proposed mechanisms/
comment
Clopidogrel ↑ bleeding risk Moderate, level B Increased conversion to active 
metabolite
CYP1A2, CYP2C9, CYP3A4 
substrates e.g. imatinib, 
indinavir, tacrolimus, 
carbamazepine, phenytoin
↓ drug levels and 
effect
CYP3A4 = Major, 
level B
CYP1A2, CYP2C9 = 
Moderate, level B
Induces CYP enzymes
Non-nucleoside reverse 
transcriptase inhibitors, 
protease inhibitors
↓ drug levels and 
effect
Major, level B Induces CYP3A4
Oral contraceptives ↓ drug levels Major, level B Risk of breakthrough bleeding/
contraceptive failure 
P-glycoprotein substrates 
e.g. digoxin, fexofenadine, 
irinotecan
↓ drug levels and 
effect 
Major, level B Induces intestinal 
P-glycoprotein 
Simvastatin ↓ drug levels Moderate, level B Statin levels reduced by up to 
28%
Warfarin ↓ drug effect Major, level B Induces CYP1A2, CYP2C9 and 
CYP3A4
Valerian Alprazolam ↑ drug levels Major, level B CYP3A4 inhibitor. Alprazolam 
increased by 19% in one study.
CNS depressants ↑ drug effect Major, level D Pharmacodynamic effect
CYP3A4 substrates ↑ substrate effect Moderate, level D
CYP cytochrome P450     
INR international normalised ratio      
CNS central nervous system
* Interaction rating adapted from Natural Medicines Comprehensive Database.11 The level of severity (major, 
moderate, minor) has been calculated using the evidence and probability of harm. This rating is linked with a generic 
recommendation for management.
Major Strongly discourage patients from using this combination as a serious adverse outcome could occur. If used,   
 patient should be monitored closely for potential adverse outcomes.
Moderate Use cautiously or avoid combination as a significant adverse outcome could occur. If used, monitor for potential  
 adverse outcomes.
Minor Be aware that there is a chance of an interaction. Advise patients of symptoms that may occur and an action plan  
 to follow.
Level of evidence ratings:
A High-quality randomised controlled trial or meta-analysis 
b Non-randomised clinical trial, literature review, clinical cohort or case-control study, historical control or epidemiologic study
C Consensus or expert opinion
D Anecdotal evidence; in vitro or animal study or theoretical based on pharmacology
Finding information about complementary 
medicine interactions
Most complementary medicines are listed (AUST L) medicines, 
which are not subjected to the same rigorous premarketing 
safety and efficacy trials as registered (AUST R) medicines. Thus 
evidence of their interaction potential is often not available. In 
addition, manufacturers are not obliged to provide a consumer 
medicine information leaflet with advice or warnings regarding  
complementary medicine interactions. 
Despite the lack of hard data, health professionals still need to 
make reasonable recommendations to patients about potential 
interactions. With a view to helping Australians make more 
informed decisions about using complementary medicines, 
an independent consortium from Mater Health Services 
Brisbane, Bond University and University of Queensland, 
with funding from the National Prescribing Service, evaluated 
complementary medicines information resources in 2008.12 
Specific criteria were used to identify 52 resources – 26 of these 
...Table continued
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were shortlisted and assessed for technical quality, content and 
clinical utility. The quality of drug interaction information was 
also assessed in the review, specifically whether mechanisms 
were outlined, degree of severity was stated, and whether the 
absence of known drug interactions was disclosed. 
While many resources (free or subscription) had technical 
strengths, few had comprehensive interaction coverage. 
Those with some detail are included for further reading. Two 
of the highest ranked resources were online subscription 
databases, both of which contained reasonably comprehensive 
complementary medicine–drug interaction checkers. These 
were:
n Natural Standard (www.naturalstandard.com), which 
provides detailed monographs and brief summaries  
('bottom line')
n Natural Medicines Comprehensive Database  
(www.naturaldatabase.com). 
Conclusion
Consumers frequently use complementary medicines in 
combination with conventional medicines. For this reason, 
health professionals should always consider the potential for 
pharmacodynamic and pharmacokinetic interactions between 
them. High quality evidence is increasingly available for 
identification and prevention of these interactions. 
References
1. Therapeutic Goods Administration. The regulation of 
complementary medicines in Australia – an overview. April 
2006.  
www.tga.gov.au/cm/cmreg-aust.htm (information last 
reviewed 2007 Apr 24) [cited 2010 Nov 16] 
2. Kotsirilos V. GPs' attitudes toward complementary medicine. 
Aust Fam Phys 2007;36:270-1.
3. Australian Bureau of Statistics. Australian Social Trends, 
2008 Paper 4102.0.  
www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/ 
4102.0Chapter5202008 [cited 2010 Nov 16]
4. Nahin RL, Pecha M, Welmerink DB, Sink K, DeKosky ST, 
Fitzpatrick AL. Concomitant use of prescription drugs and 
dietary supplements in ambulatory elderly people.  
J Am Geriatr Soc 2009;57:1197-205. 
5. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. 
Incidence and severity of potential drug-dietary supplement 
interactions in primary care patients: an exploratory study of 
2 outpatient practices. Arch Intern Med 2004;164:630-6. 
6. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P,  
Lindau ST. Use of prescription and over-the-counter 
medications and dietary supplements among older adults in 
the United States. JAMA 2008;300:2867-78.
7. Cadieux RJ. Drug interactions in the elderly. How multiple 
drug use increases risk exponentially. Postgrad Med 
1989;86:179-86.
8. Boullata J. Natural health product interactions with 
medication. Nutr Clin Pract 2005;20:33-51.
9. Dietary supplements – a framework for evaluating safety. 
Institute of Medicine. Washington, DC: The National 
Academies Press; 2005. p. 235-46.  
www.nap.edu/books/0309091101/html [cited 2010 Nov 16]
10. MacGregor JT, Collins JM, Sugiyama Y, Tyson CA, Dean J, 
Smith L. In vitro human tissue models in risk assessment: 
report of a consensus-building workshop. Toxicol Sci 
2001;59:17-36. 
11. Jellin JM, editor. Natural medicines comprehensive 
database. Therapeutic Research Faculty, Stockton (CA), USA.  
www.naturaldatabase.com [cited 2010 Nov 16] 
12. McGuire TM, Walters JA, Dean AJ, Van Driel M, Del Mar C, 
Kotsirilos V, et al. Review of the quality of complementary 
medicines information resources: summary report. Sydney: 
National Prescribing Service; 2009.  
www.nps.org.au/__data/assets/pdf_file/0005/69656/
CMsInfoSummary.pdf [cited 2010 Nov 16]
13. Bjerrum L, Gonzalez Lopez-Valcarcel B, Petersen G. Risk 
factors for potential drug interactions in general practice.  
Eur J Gen Pract 2008;14:23-9.
14. Barnes J, Anderson LA, Phillipson JD. Herbal interactions. 
Pharm J 2003;270:118-21. 
Further reading
Barnes J, Anderson LA, Phillipson JD. Herbal medicines. 3rd ed.  
London: Pharmaceutical Press; 2007. (book, or as part of 
MedicinesComplete)
Stockley's Drug Interactions. Baxter K, editor. London: Royal 
Pharmaceutical Society of Great Britain; 2010. (book, or as part 
of MedicinesComplete) 
Braun L, Cohen M. Herbs and natural supplements: an  
evidence-based guide. 3rd ed. Sydney: Elsevier Australia; 2010. 
The review of natural products. In: Facts & Comparisons.  
5th ed. 2008. Wolters Kluwer.  
www.factsandcomparisons.com/review-of-natural-products-
bound.aspx [cited 2010 Nov 16]
Kuhn MA, Winston D. Winston and Kuhn's herbal therapy and 
supplements, a scientific and traditional approach. 2nd ed. 
Philadelphia (PA): Wolters Kluwer, Lippincott Williams & Wilkins; 
2008. 
Therapeutic Goods Administration. Black cohosh (Cimicifuga 
racemosa): New labelling requirements and consumer 
information for medicines containing Black cohosh.  
www.tga.gov.au/cm/0705blkcohosh.htm [cited 2010 Nov 16]
Therapeutic Goods Administration. Kava – safety alerts & 
advisory statements.  
www.tga.gov.au/alerts/kava.htm [cited 2010 Nov 16]
Conflict of interest: none declared
Self-test questions
The following statements are either true or false  
(answers on page 198)
3. St John's wort can decrease phenytoin concentrations 
via its induction of cytochrome P450 3A4.
4. Ginkgo can increase the bleeding risk when given with 
warfarin.
